Navigation Links
Roth in Medical News

Cardiac Science to Present at the Roth 21st Annual OC Growth Stock Conference

BOTHELL, Wash., Feb. 17 /PRNewswire-FirstCall/ -- Cardiac Science (Nasdaq: CSCX ), a global leader in advanced cardiac diagnosis, resuscitation, rehabilitation, and informatics products, today announced today that it will present at the Roth 21st Annual OC Growth Stock Conference at the Ritz Car...

Matrixx Initiatives, Inc. to Present at the Roth Capital Partners 21st Annual OC Growth Stock Conference

SCOTTSDALE, Ariz., Feb. 13 /PRNewswire-FirstCall/ -- Matrixx Initiatives, Inc. (Nasdaq: MTXX ), an over-the-counter healthcare company that develops and markets products that provide consumers with "Better Ways to Get Better(R)," will be presenting on Tuesday February 17, 2009, at the Roth Capit...

Smart Balance to Webcast Presentation at Roth Capital Partners Growth Stock Conference

PARAMUS, N.J., Feb. 13 /PRNewswire-FirstCall/ -- Smart Balance, Inc. (Nasdaq: SMBL ) announced today Steven Hughes, Chairman and Chief Executive Officer of Smart Balance, Inc., will make a presentation at the Roth Capital Partners 21st Annual Growth Stock Conference in Dana Point, CA, at 2 p.m. ...

Micromet To Present at the ROTH 21st Annual Orange County Growth Stock Conference

BETHESDA, Md., Feb. 13 /PRNewswire-FirstCall/ -- Micromet, Inc. (Nasdaq: MITI ), today announced that its Chief Financial Officer, Buck Phillips, will present at the ROTH 21st Annual Orange County Growth Stock Conference at the Ritz-Carlton Laguna Niguel on Wednesday, February 18, 2009. ...

NeoGenomics to Present at the Roth Capital Partner's 21st Annual OC Growth Stock Conference

FT. MYERS, Fla., Feb. 11 /PRNewswire-FirstCall/ -- NeoGenomics, Inc. (OTC Bulletin Board: NGNM), a leading provider of cancer genetics testing services, announced today that President and Chief Scientific Officer, Bob Gasparini, will present at the Roth Capital Partner's 21st Annual OC Growth Stoc...

NuVasive to Present at ROTH 21st Annual OC Growth Stock Conference

SAN DIEGO, Feb. 10 /PRNewswire-FirstCall/ -- NuVasive, Inc. (Nasdaq: NUVA ), a medical device company focused on developing products for minimally disruptive surgical treatments for the spine, announced today that Kevin O'Boyle, Executive Vice President & Chief Financial Officer, is schedule...

VNUS Medical Technologies to Present at the Roth 21st Annual OC Growth Stock Conference

SAN JOSE, Calif., Feb. 9 /PRNewswire-FirstCall/ -- VNUS(R) Medical Technologies, Inc. (Nasdaq: VNUS ), a leading provider of medical devices for the minimally invasive treatment of venous reflux disease, today announced its plans to present at the Roth 21st Annual OC Growth Stock Conference,...

Masimo to Present at the Roth Capital Partners 21st Annual OC Growth Stock Conference

IRVINE, Calif., Feb. 6 /PRNewswire-FirstCall/ -- Masimo Corporation (Nasdaq: MASI ), the inventor of Pulse CO-Oximetry(TM) and Measure-Through Motion and Low-Perfusion pulse oximetry, today announced that its management is scheduled to present at the Roth Capital Partners 21st Annual OC Growth S...

Align Technology Executives to Present at ROTH 21st Annual OC Growth Stock Conference

SANTA CLARA, Calif., Feb. 4 /PRNewswire-FirstCall/ -- Align Technology, Inc. (Nasdaq: ALGN ), the inventor of Invisalign(R), a proprietary method of straightening teeth without wires and brackets, announced today that Thomas M. Prescott, president and CEO, and Kenneth Arola, vice president and C...

Shengtai Pharmaceutical to Present at Roth 21st Annual OC Growth Stock Conference

WEIFANG, Shandong, China, Feb. 3 /PRNewswire-Asia-FirstCall/ -- Shengtai Pharmaceutical, Inc. (OTC Bulletin Board: SGTI) ("Shengtai Pharmaceutical" or "the Company"), a leading manufacturer and distributor of high-quality, pharmaceutical grade glucose products in China, today announced that it...

More>>

Roth in Medical Technology

'Hibernation-On-Demand' Drug Hydrogen Sulfide Significantly Improves Survival After Extreme Blood Loss

...tion of that soldier to an area where he or she can get medical attention," roth said. Roth's study, which attempted to mimic a similar scenario, involved...hemorrhage and must be replaced to maintain life processes. In April 2005 roth and colleagues made headlines worldwide when they reported, in the journal ...

Phase III Data Show Vanda Pharmaceuticals' Tasimelteon (VEC-162) Significantly Improves Sleep in Patients with Chronic Insomnia

...2008. 6. D'Alonzo GE, Krachman SL. Circadian rhythm sleep disorders. JAOA. 2000;100(8):S15-21. 7. Drake CL, Roehrs T, Richardson G, Walsh JK, roth T. Shift work sleep disorder: prevalence and consequences beyond that of symptomatic day workers. Sleep. 2004;27:1453-62. 8. Carney PR, Be...

Arena Pharmaceuticals Presented Positive Phase 2a Clinical Trial Results of APD125 for the Treatment of Insomnia at 22nd Annual Meeting of the Associated Professional Sleep Societies

...rena Pharmaceuticals, Inc. (Nasdaq: ARNA ) announced today that Dr. Thomas roth of Henry Ford Hospital presented data from Arena's positive Phase 2a clinic...many patients looking to achieve better 'quality sleep'," stated Dr. Thomas roth of Henry Ford Hospital, who interpreted the PSG data for the Phase 2a trial...

Ikaria Completes Dosing of Phase 1a Clinical Study for IK-1001 (Sodium Sulfide) for Injection

...ths speaks volumes about the quality and innovative spirit of the R&D group at Ikaria." In a landmark article in the prestigious journal, Science, Dr. roth demonstrated the ability of hydrogen sulfide to induce a state of reversible metabolic hibernation in mice. Ikaria's hydrogen sulfide clinical platfor...

Arena Pharmaceuticals Announces Positive Phase 2 Clinical Trial Results of APD125 for the Treatment of Insomnia

...eatment of insomnia patients who have difficulty maintaining sleep. "APD125 clearly has robust sleep maintenance properties," according to Dr. Thomas roth of Henry Ford Hospital, who interpreted the polysomnography data for the Phase 2 trial. "In the trial, APD125 consolidated sleep in ways that are not ...

Protalix BioTherapeutics Treats First Patient in Phase III Clinical Trial of prGCD

...ormation. For additional information, contact Protalix BioTherapeutics at: investors@protalix.com AMEX IR Alliance for Protalix BioTherapeutics Lee roth / David Burke 212-896-1209 / 1258 lroth@kcsa.com / dburke@kcsa.com ...
Roth in Biological News

Anadys Pharmaceuticals to Present at the Roth OC Growth Stock Conference

SAN DIEGO, Feb. 9 /PRNewswire-FirstCall/ -- Anadys Pharmaceuticals, Inc. (Nasdaq: ANDS ) announced today that it will present at the 21st Annual Roth OC Growth Stock Conference on Monday, February 16, 2009 at 1:00 p.m. PST (4:00 p.m. EST). The conference is being held at The Ritz-Carlton, Lagun...

The Burnham buzz

...chemokine promotes the spread of tumors, particularly in breast cancer. Dr. roth believes that compounds that block the chemokine may be potential cancer th... bind to chemokines only bind weakly, making them poor drug candidates. Dr. roth and a team of Burnham chemists are working to custom-design molecules that ...

Dual gene therapy suppresses lung cancer in preclinical test

...nes repeatedly express either p53 or FUS1 tumor-suppressing proteins. roth expects the research team to advance combination therapies to clinical tria...xic, with fewer side effects, than other types of combined cancer therapy," roth says. "These genes don't have much effect on normal tissue or normal cells ...

Intravenous nanoparticle gene therapy shows activity in stage IV lung cancer

...cancer in a mouse model. FUS1 was discovered by a research team led by roth at M. D. Anderson and by John Minna, M.D., of the Department of Internal M...esearch, at The University of Texas Southwestern Medical Center at Dallas. roth and Minna are the co-principal investigators of a National Cancer Institut...

Temple University Hospital investigates treatment for cervical dysplasia

...ility of two preventive vaccines may lower the incidence of HPV infection and reduce the risk of cervical cancer," said Enrigue Hernandez, The Abraham roth Professor and Chair of the Department of Obstetrics and Gynecology at Temple University Hospital and School of Medicine. "However, for those women alr...

U-M team recovers ancient whale in Egyptian desert

...ists and in operating rooms, ERs and battlefields, roth said. "Manipulating this metabolic mechanism fo...ses without damaging healthy tissue. Cancer cells, roth explained, aren't dependent on oxygen to grow. As ...rounding healthy cells, which need oxygen to live. roth hypothesizes that temporarily eliminating oxygen d...

Buying Time Through Hibernation on Demand

...ists and in operating rooms, ERs and battlefields, roth said. "Manipulating this metabolic mechanism fo...ses without damaging healthy tissue. Cancer cells, roth explained, aren't dependent on oxygen to grow. As ...rounding healthy cells, which need oxygen to live. roth hypothesizes that temporarily eliminating oxygen d...
Roth in Biological Technology

Volcano Corporation Presentation at Roth Capital Partners Conference to Be Webcast

SAN DIEGO, Feb. 12 /PRNewswire-FirstCall/ -- Volcano Corporation (Nasdaq: VOLC ), a leader in the development, manufacturing and sales of products for the diagnosis and treatment of coronary and peripheral artery disease, said today that it will be participating in the Roth Capital Partners ...

Cadence Pharmaceuticals' CEO Theodore Schroeder to Present at the Roth Capital Partners 21st Annual OC Growth Stock Conference

SAN DIEGO, Feb. 10 /PRNewswire-FirstCall/ -- Cadence Pharmaceuticals, Inc. (Nasdaq: CADX ), a biopharmaceutical company focused on in-licensing, developing and commercializing proprietary product candidates principally for use in the hospital setting, announced today that the company's Presi...

China-Biotics, Inc. to Present at Roth Capital Partners 21st Annual OC Growth Stock Conference

SHANGHAI, China, Feb. 10 /PRNewswire-Asia-FirstCall/ -- China-Biotics, Inc. (Nasdaq: CHBT ) ("China-Biotics", "the Company"), a leading Chinese firm specializing in the manufacture, research, development, marketing and distribution of probiotics products, today announced members of the Compa...

Yongye Biotechnology to Present at Roth Conference

BEIJING, Feb. 9 /PRNewswire-Asia-FirstCall/ -- Yongye Biotechnology International, Inc. (OTC Bulletin Board: YGYB; "Yongye" or the "Company"), a leading developer, producer and distributor of nutrients for plants and animals, located in the People's Republic of China, today announced that the ...

China Sky One Medical, Inc. CFO to Present at Roth Conference

HARBIN, China, Feb. 6 /PRNewswire-Asia-FirstCall/ -- China Sky One Medical, Inc. ("China Sky One Medical" or "the Company") (Nasdaq: CSKI ), a leading fully integrated pharmaceutical company producing over-the-counter drugs in the People's Republic of China ("PRC"), today announced that the ...

Yongye Biotechnology to Present at Roth Capital 'China Comes to Vegas' Conference

BEIJING, Nov. 10 /Xinhua-PRNewswire-FirstCall/ -- Yongye Biotechnology International, Inc. (OTC Bulletin Board: YGYB; "Yongye" or the "Company"), a leading developer, producer and distributor of nutrients for plants and animals, located in the People's Republic of China, today announced that t...

China Yingxia to Present at Roth China Comes to Vegas Conference

HARBIN, China, Nov. 4 /Xinhua-PRNewswire-FirstCall/ -- China Yingxia International, Inc. (OTC Bulletin Board: CYXI) ("China Yingxia" or "the Company"), a leading provider in the health and nutritional food industry engaged in the development, manufacture and distribution of nutritional food pr...

Sinovac to Present at the Brean Murray, Carret & Co. All-Cap All-China Conference and the Roth China Discovery Tour 2008

BEIJING, May 7 /Xinhua-PRNewswire/ -- Sinovac Biotech Ltd. (Amex: SVA ), a leading provider of vaccines in China, today announced that Mr. Weidong Yin, CEO, and Ms. Helen Yang, International Business Manager, are scheduled to present at the Brean Murray, Carret & Co. All-Cap All-China Confere...

NeurogesX to Present at Roth 2008 OC Growth Stock Conference

SAN MATEO, Calif., Feb. 19 /PRNewswire-FirstCall/ -- NeurogesX, Inc. (Nasdaq: NGSX ), a biopharmaceutical company focused on developing novel pain management therapies, announced today that it is scheduled to present at the Roth Capital Partners 20th Annual OC Growth Stock Conference in Lagun...

AEterna Zentaris to Present at the Upcoming Roth Capital Partners 20th Annual OC Growth Stock Conference in Dana Point, California

QUEBEC CITY, Feb. 19 /PRNewswire-FirstCall/ - AEterna Zentaris Inc. (NASDAQ: AEZS , TSX: AEZ), a global biopharmaceutical company focused on endocrine therapy and oncology, today announced that its President and CEO, David J. Mazzo, Ph.D., will present a company overview at the Roth Capital P...
Roth in Biological Dictionary

Transgenic

...r creating transgenic animals is constantly improving and will ... CWRU Transgenic Mice and Knockout Mice: Transgenic Core Facility ... The roth lab developed transgenic mice in which activity of specific neuronal ... [ANDi, the first transgenic Rhesus monkey, carries the gene for a gr...
Other Tags
(Date:8/21/2014)... 21, 2014 The report "Industrial ... Pollutant Control System (FGD, DeNOx, Particulate Control, Mercury ... Steel, Chemical & Others) - Global Trends & ... industrial flue gas treatment systems & services market ... size in terms of value. The industrial flue ...
(Date:8/21/2014)... Revista, a one-stop source for ... data, is “on a roll.” Today, the Annapolis-based ... the Southeast, Mid-Atlantic and Midwest areas of the ... widely available, comprehensive medical property database tracking these ... properties, including existing and recently added, is 34,549. ...
(Date:8/21/2014)... HealthDay Reporter THURSDAY, Aug. 21, 2014 ... dropped nearly 12 percent in the last decade, a new ... of teens using indoor tanning beds barely decreased. Both indoor ... skin cancers, including deadly melanomas, the researchers noted. "Unfortunately, ... who reported wearing sunscreen, from 67.7 percent in 2001 to ...
(Date:8/21/2014)... 21, 2014 Pleio, Inc., a ... launching a new suite of services for retail ... retail pharmacy by applying proven behavior shaping programs ... in increased medication adherence, higher PDC scores and ... Pleio’s PDC-targeted offerings align retail’s desire to meet ...
(Date:8/21/2014)... 2014 When children go back to school, ... cause them to become sick and risk missing school. It ... help them fight these germs to ensure a successful school ... just that with its XFactor program. , The XFactor program ... multi-vitamins. Children ages 4 and up can receive 30-day supplies ...
Breaking Medicine News(10 mins):Health News:Industrial Flue Gas Treatment Systems Market Estimated to Worth $59, 546.7 Million by 2019 – Report by MarketsandMarkets 2Health News:Industrial Flue Gas Treatment Systems Market Estimated to Worth $59, 546.7 Million by 2019 – Report by MarketsandMarkets 3Health News:Industrial Flue Gas Treatment Systems Market Estimated to Worth $59, 546.7 Million by 2019 – Report by MarketsandMarkets 4Health News:Revista Medical Property Data Now Available for the Mid-Atlantic, Southeast and Midwest Regions 2Health News:Revista Medical Property Data Now Available for the Mid-Atlantic, Southeast and Midwest Regions 3Health News:Revista Medical Property Data Now Available for the Mid-Atlantic, Southeast and Midwest Regions 4Health News:Revista Medical Property Data Now Available for the Mid-Atlantic, Southeast and Midwest Regions 5Health News:Fewer U.S. Teens Using Sunscreen, Study Finds 2Health News:Pleio, Inc. Expands Adherence Offerings For Retail Pharmacy 2Health News:MedX Pharmacy Helps with Back to School Preparation 2
(Date:8/20/2014)... the University of Tbingen, Arizona State University, the Wellcome ... Health Institute (Swiss TPH) isolated Mycobacterium pinnipedii ... 1000 years old. The pathogen is a relative of ... causes disease in humans today. These researchers assume that ... coast. "The link to sea lions was unexpected" comments ...
(Date:8/20/2014)... Using population-based screening outcomes of approximately 3 million ... four researchers at the University of Massachusetts Medical School, ... (SCID) can be successfully implemented across public health newborn ... in the Aug. 20 issue of the Journal ... showed the rate of SCID in newborns is higher ...
(Date:8/20/2014)... has awarded the Oklahoma Medical Research Foundation a five-year, ... and the bacteria,s effects on humans. , For ... colleagues have studied the human immune response to anthrax ... Immunology. The original funding came soon after anthrax-laced letters ... the terrorist attacks of Sept. 11, 2001. , ...
Breaking Biology News(10 mins):Newborn screening expansion offers early diagnosis and treatment to infants with SCID 2Newborn screening expansion offers early diagnosis and treatment to infants with SCID 3$14.5 million grant awarded to continue anthrax studies 2
Other Contents